Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 116


IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T.

Lancet Oncol. 2016 Oct 3. pii: S1470-2045(16)30408-9. doi: 10.1016/S1470-2045(16)30408-9.


The use of injectable calcium hydroxylapatite in the surgically pretreated larynx with glottal insufficiency.

Caffier PP, I Nasr A, Weikert S, Rummich J, Gross M, Nawka T.

Laryngoscope. 2016 Aug 31. doi: 10.1002/lary.26261.


The Value of Vocal Extent Measure (VEM) Assessing Phonomicrosurgical Outcomes in Vocal Fold Polyps.

Salmen T, Ermakova T, Möller A, Seipelt M, Weikert S, Rummich J, Gross M, Nawka T, Caffier PP.

J Voice. 2016 Apr 21. pii: S0892-1997(16)30102-3. doi: 10.1016/j.jvoice.2016.03.016.


Current Practice: The Bilobed Flap from the Classic Indication to Cover a Small Defect on Face to Covering a Large Defect on the Chest.

Bast F, Roos S, Weikert S, Schrom T.

J Coll Physicians Surg Pak. 2016 Mar;26(3):220-2. doi: 03.2016/JCPSP.220222.


Doping of Graphene by Low-Energy Ion Beam Implantation: Structural, Electronic, and Transport Properties.

Willke P, Amani JA, Sinterhauf A, Thakur S, Kotzott T, Druga T, Weikert S, Maiti K, Hofsäss H, Wenderoth M.

Nano Lett. 2015 Aug 12;15(8):5110-5. doi: 10.1021/acs.nanolett.5b01280.


Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.

Bergmann L, Kube U, Doehn C, Steiner T, Goebell PJ, Kindler M, Herrmann E, Janssen J, Weikert S, Scheffler MT, Schmitz J, Albrecht M, Staehler M.

BMC Cancer. 2015 Apr 18;15:303. doi: 10.1186/s12885-015-1309-7.


Evaluation of perioperative complications in open and laparoscopic surgery for renal cell cancer with tumor thrombus involvement using the Clavien-Dindo classification.

Ebbing J, Wiebach T, Kempkensteffen C, Miller K, Bachmann A, Günzel K, Rieken M, Friedersdorff F, Baumunk D, Weikert S.

Eur J Surg Oncol. 2015 Jul;41(7):941-52. doi: 10.1016/j.ejso.2015.02.009.


Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition.

Rohrmann S, Linseisen J, Overvad K, Lund Würtz AM, Roswall N, Tjonneland A, Boutron-Ruault MC, Racine A, Bastide N, Palli D, Agnoli C, Panico S, Tumino R, Sacerdote C, Weikert S, Steffen A, Kühn T, Li K, Khaw KT, Wareham NJ, Bradbury KE, Peppa E, Trichopoulou A, Trichopoulos D, Bueno-de-Mesquita HB, Peeters PH, Hjartåker A, Skeie G, Weiderpass E, Jakszyn P, Dorronsoro M, Barricarte A, Santiuste de Pablos C, Molina-Montes E, de la Torre RA, Ericson U, Sonestedt E, Johansson M, Ljungberg B, Freisling H, Romieu I, Cross AJ, Vergnaud AC, Riboli E, Boeing H.

Int J Cancer. 2015 Mar 1;136(5):E423-31. doi: 10.1002/ijc.29236.


Impact of thoracic epidural analgesia on blood loss in radical retropubic prostatectomy.

Baumunk D, Strang CM, Kropf S, Schäfer M, Schrader M, Weikert S, Cash H, Breckwoldt J, Miller K, Hachenberg T, Schostak M.

Urol Int. 2014;93(2):193-201. doi: 10.1159/000360300.


Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.

Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, Burkholder I, Bergmann L.

J Cancer Res Clin Oncol. 2014 May;140(5):823-7. doi: 10.1007/s00432-014-1610-x.


Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma.

Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F, Magheli A, Miller K, Grünwald V, Weikert S.

Eur J Cancer. 2014 Feb;50(3):563-9. doi: 10.1016/j.ejca.2013.10.017.


Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).

Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V.

Br J Cancer. 2013 Dec 10;109(12):2998-3004. doi: 10.1038/bjc.2013.662.


N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.

Pesch B, Gawrych K, Rabstein S, Weiss T, Casjens S, Rihs HP, Ding H, Angerer J, Illig T, Klopp N, Bueno-de-Mesquita B, Ros MM, Kaaks R, Chang-Claude J, Roswall N, Tjønneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Dossus L, Boeing H, Weikert S, Trichopoulos D, Palli D, Sieri S, Tumino R, Panico S, Quirós JR, González C, Sánchez MJ, Dorronsoro M, Navarro C, Barricarte A, Ljungberg B, Johansson M, Ulmert D, Ehrnström R, Khaw KT, Wareham N, Key TJ, Ferrari P, Romieu I, Riboli E, Brüning T, Vineis P.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2055-65. doi: 10.1158/1055-9965.EPI-13-0119-T.


Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.

Schrader AJ, Seseke S, Keil C, Herrmann E, Goebell PJ, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T.

Eur Urol. 2014 Aug;66(2):275-81. doi: 10.1016/j.eururo.2013.08.055.


miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.

Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, Jung K.

J Mol Diagn. 2013 Sep;15(5):695-705. doi: 10.1016/j.jmoldx.2013.05.008.


Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M.

BMC Med Inform Decis Mak. 2013 Aug 5;13:83. doi: 10.1186/1472-6947-13-83.


Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer.

Tölle A, Jung M, Rabenhorst S, Kilic E, Jung K, Weikert S.

Oncol Rep. 2013 Oct;30(4):1949-56. doi: 10.3892/or.2013.2621.


Practical management of everolimus-related toxicities in patients with advanced solid tumors.

Grünwald V, Weikert S, Pavel ME, Hörsch D, Lüftner D, Janni W, Geberth M, Weber MM.

Onkologie. 2013;36(5):295-302. doi: 10.1159/000350625. Review.


Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.

Bergmann L, Goebell PJ, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler MD, Steiner T, Overkamp F, Albrecht M, Guderian G, Doehn C.

Onkologie. 2013;36(3):95-100. doi: 10.1159/000348522.


[Significance of the sinus x-ray prior to septoplasty].

Bast F, Weikert S, Schrom T.

HNO. 2013 Jul;61(7):651-5. doi: 10.1007/s00106-013-2671-x. German.

Items per page

Supplemental Content

Loading ...
Support Center